Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Tyk2 Gene Editing 
Non-receptor tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family containing three additional members (JAK1-3). JAK binds to a variety of cytokines and growth factor receptors and undergoes self and/or cross-phosphorylation upon ligand binding. Activated JAK phosphorylates members of the signal transduction and activators of transcription (STAT) family and activates several cytokines and type I interferons (IFNs). Structurally, TYK2 shares a conserved structure of seven JAK homology (JH) domains with other JAKs, wherein the C-terminal JH1 and JH2 encode a kinase and a pseudokinase domain, respectively, and the N-terminal portion provides a protein-protein interaction domain. TYK2 kinase activity is essential for undisturbed signaling, which does not exert inhibition while losing kinase activity. And more importantly, TYK2 protein stability is dependent on JH1-mediated kinase activity, which is very beneficial in the future development of Tyk2 inhibitors as a target therapeutic for human diseases.
Studies have shown that inhibition of TYK2 inhibits double-stranded RNA-induced apoptosis in human pancreatic cancer β-cells by reducing type I IFN-STAT signaling and preventing the increased expression of major histocompatibility complex (MHC)-like proteins. And there is a link between TYK2 gene variants and autoimmune diseases (such as systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, and type 1 diabetes, etc.), inflammatory diseases, and tumors. Moreover, the function of TYK2 has been extended from effective tumor surveillance to true oncogenes. Therefore, TYK2 is an attractive therapeutic intervention target. Future work will need to further describe the structure-function relationship and fully understand the involvement of TYK2 in the immune regulation network.
Tyk2 Gene Editing Service
As a leading gene editing biotechnology company, CRISPR/Cas9 PlatformCB is committed to offering CRISPR/Cas9 gene editing. Our scientists have deep gene editing knowledge and extensive experience in experimental operation and data processing. Based on our platform, we help you effectively control target genes knockout/knockin/point mutation in cells or animals via CRISPR/Cas9 technology.
- Tyk2 Gene Editing Cell Line Generation
With advanced national-level labs, a team of professional scientists, and extensive experience with cell culture and CRISPR system application, CRISPR/Cas9 PlatformCB has successfully implemented Tyk2 CRISPR/Cas9 gene edit in both easy-to-transfect cell lines and hard-to-transfect cells. Tell us your needs, we will offer you professional custom Tyk2 gene editing services from strategy design to final stable cells. Our Tyk2 gene editing cell line generation services include:
✧ SgRNA design and synthesis
✧ Transfect the cell line you interest
✧ Select the high expression cell and sort monoclonal cell
✧ Validate the knockout/knockin/point mutation of Tyk2 by PCR and sequencing
✧ Produce cryogenic preserved vials of stable cells and a final report
Typically, we develop CRISPR-mediated gene editing cell lines, including HEK239T, Hela, HepG2, U87, but we can use other cell lines according to your requirements.
Host cell line: Ba/F3, CHO, MDA-MB-453, MDA-, MB-231NIH3T3, T47D, Neuro2a, MCF7, RKO, K562, RAW264.7, etc.
- Tyk2 Gene Editing Animal Model Generation
CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR-Cas9 technology into animal models, which have been fully recognized by our clients. According to your projects' needs, we provide a one-stop-shop Tyk2 CRISPR/Cas9 gene editing animal services and guarantee at least 2 founders or 3 F1 animals y with shorter turnaround time and lower price. Our Tyk2 gene editing animal model generation services include:
➢ Tyk2 gene conventional knockout animals
➢ Tyk2 gene conditional knockout animals
➢ Tyk2 point mutation animals
➢ Tyk2 knockin animals
Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.
CRISPR/Cas9 PlatformCB is devoted to providing the best gene editing services to accelerate the achievement of your research goals. Our one-stop service range from strategy design to final stable cell lines or F1 animals. In addition, customized service has been provided to meet your special requirements. Excellent quality management and quality assurance capacity being highly praised by customers. There is no doubt that CRISPR/Cas9 PlatformCB will be your best partner to support your research. If you have any project need CRISPR system, don't hesitate to contact us.
Related Products at CRISPR/Cas9 PlatformCB
| CATALOG NO. | PRODUCT NAME | INQUIRY |
| CLKO-0709 | TYK2 KO Cell Lysate-HEK293T | Inquiry |
| CSC-RT0451 | TYK2 Knockout Cell Line-293T | Inquiry |
References:
- Haan C. et al. Jaks and cytokine receptors–an intimate relationship. Biochem Pharmacol. 2006; 72: 1538–1546.
- Wilks AF. et al. The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol. 2008; 19: 319–328.
- Michaela Prchal-Murphy. et al. TYK2 Kinase Activity Is Required for Functional Type I Interferon Responses in Vivo. 2012 June 18;
- Laura Marroqui. et al. TYK2, a Candidate Gene for Type 1 Diabetes, Modulates Apoptosis and the Innate Immune Response in Human Pancreatic β-Cells. Diabetes. 2015 Nov; 64(11): 3808-3817.
- Nicole R.Leitner. et al. Tyrosine kinase 2 – Surveillant of tumours and bona fide oncogene. Cytokine. 2017; 89:209-218.
- Michaela Prchal-Murphy. et al. TYK2 Kinase Activity Is Required for Functional Type I Interferon Responses in Vivo. PLoS One. 2012; 7(6): e39141.